June 30, 2021
With preparations underway to bring Carolina’s approximately 12,300 employees back to campus by July 19 after mostly working remotely since March 2020, the University announced revised COVID-19 community standards that will take effect before...Read More
June 24, 2021
Scientists at UNC’s Gillings School of Global Public Health have developed a vaccine they say could be effective against COVID-19, its variants — and a future coronavirus pandemic. While no one knows which virus may...Read More
New research from the University suggests that people who have had COVID-19 may need only one shot of vaccine.
The study, led by UNC’s School of Medicine and the Gillings School of Global Public Health, showed one dose of either the Pfizer-BioNTech or Moderna vaccine — known as mRNA vaccines — boosted antibodies among those who previously had COVID-19.
“These results support a new and growing body of research suggesting that prior coronavirus infection may act as a primer for the immune response to the first dose of mRNA-based COVID-19 vaccine,” said first study author Dr. Emily Ciccone, a clinical instructor and fellow in the medical school’s Division of Infectious Diseases.
“If this immune response is shown to be durable and protective against subsequent infection in future studies, individuals with a history of infection may be able to forgo the second dose of an mRNA-based vaccine,” Ciccone said.
The potential for some Americans to skip a second shot could free up urgently needed vaccine doses.
While the findings have not been peer-reviewed, the results are consistent with other studies.
The results come from UNC’s COVID Health Care Personnel Study, a joint initiative between the medical school, the Gillings school and the UNC Institute for Global Health and Infectious Diseases. Researchers followed 193 health workers who submitted to routine tests for antibodies — a key part of the body’s response to fight infections such as COVID-19.
Study participants had the opportunity to receive a COVID-19 vaccine through UNC Health’s vaccination program starting in December 2020. After one dose, the antibody response in those who previously had COVID-19 was almost twice as high as those with no signs of previous infection.
“Moreover, the response to the first vaccination among individuals with prior infection was of similar magnitude to the response to two vaccine doses among those who had never been infected,” said corresponding study author Allison Aiello ’98 (MS), professor of epidemiology at the Gillings school.
There was a limited number of people with a prior infection in the UNC study group. Despite the small sample size, researchers revealed a significant difference in response to the first vaccination that has been corroborated by recent studies.
The UNC study stands out because researchers were able to measure antibody responses before and after vaccination, in some cases for months prior to the first vaccine dose.